-
European Psychiatry. 01/2012; 27:1.
-
K Domschke,
A Reif,
H Weber,
J Richter,
C Hohoff,
P Ohrmann, A Pedersen,
J Bauer,
T Suslow,
H Kugel, [......],
T Lang,
G W Alpers,
A Ströhle,
L Fehm,
A T Gloster,
H-U Wittchen,
V Arolt,
P Pauli,
A Hamm,
J Deckert
[show abstract]
[hide abstract]
ABSTRACT: Animal studies have suggested neuropeptide S (NPS) and its receptor (NPSR) to be involved in the pathogenesis of anxiety-related behavior. In this study, a multilevel approach was applied to further elucidate the role of NPS in the etiology of human anxiety. The functional NPSR A/T (Asn¹⁰⁷Ile) variant (rs324981) was investigated for association with (1) panic disorder with and without agoraphobia in two large, independent case-control studies, (2) dimensional anxiety traits, (3) autonomic arousal level during a behavioral avoidance test and (4) brain activation correlates of anxiety-related emotional processing in panic disorder. The more active NPSR rs324981 T allele was found to be associated with panic disorder in the female subgroup of patients in both samples as well as in a meta-analytic approach. The T risk allele was further related to elevated anxiety sensitivity, increased heart rate and higher symptom reports during a behavioral avoidance test as well as decreased activity in the dorsolateral prefrontal, lateral orbitofrontal and anterior cingulate cortex during processing of fearful faces in patients with panic disorder. The present results provide converging evidence for a female-dominant role of NPSR gene variation in panic disorder potentially through heightened autonomic arousal and distorted processing of anxiety-relevant emotional stimuli.
Molecular psychiatry 09/2011; 16(9):938-48. · 15.05 Impact Factor
-
European Neuropsychopharmacology. 01/2010; 20:S530.
-
[show abstract]
[hide abstract]
ABSTRACT: Recent research has demonstrated that attention-deficit/hyperactivity disorder (ADHD), one of the most common mental disorders in childhood, continues into adulthood. In adulthood, however, pharmacotherapy with psychostimulants still is an off-label treatment. Because of this we routinely administer a test dose of methylphenidate (MPH) prior to a continuous medication and measure MPH effects quantitatively and repeatedly employing a neuropsychological test battery. To probe if the acute effects of MPH are indeed helpful in predicting longer-term efficacy of MPH treatment we retrospectively analyzed the neuropsychological test results of 34 patients on continuous MPH medication. Two testing sessions had been performed without MPH (at baseline and 24 h after a single dose intake to control possible training effects), one after a single dose and one after 3-6 months of regular intake of MPH. A significant improvement of performance in tests assessing attentional, memory and executive functions after single medication was maintained on long term medication in those 23 patients available for follow-up. These results indicate that beneficial short term effects of MPH predict longer-term effects and may thus be helpful in the decision for an off-label treatment. Controlled prospective studies are now necessary.
Acta Neurovegetativa 02/2008; 115(2):357-62. · 2.73 Impact Factor
-
AV Rauch,
M Reker,
P Ohrmann, A Pedersen,
J Bauer,
U Dannlowski,
K Kölkebeck,
C Konrad,
H Kugel,
V Arolt,
others
Klinische Neurophysiologie 01/2008; 39(01):A203. · 0.14 Impact Factor
-
Schizophrenia Research 01/2008; 102(1-3):91-92. · 4.75 Impact Factor
-
Schizophrenia Research 01/2008; 102(1-3):188-188. · 4.75 Impact Factor
-
Schizophrenia Research 01/2008; 102(1-3):98-98. · 4.75 Impact Factor
-
M Rothermundt,
P Falkai,
G Ponath,
S Abel,
H Bürkle,
M Diedrich,
G Hetzel,
M Peters,
A Siegmund, A Pedersen,
W Maier,
J Schramm,
T Suslow,
P Ohrmann,
V Arolt
Molecular Psychiatry 11/2004; 9(10):897-9. · 13.67 Impact Factor
